# Treatment Perspectives™ Electronic Health Record

#### WHAT IS IT?

The Treatment Perspectives EHR solution provides highly targeted content delivered within the HCP's workflow. Brand creative, text, and financial messages are served up to individually or specialty-relevant targeted HCPs using real-time data, based on ICD-10–, NDC-, or CPT-based business rules.

#### RELEVATE DIFFERENTIATORS

- Local and Personalized Engagement at National Scale
  Continuous program optimization and execution for
  engagement in the right markets, to the right HCPs, at the
  right time, with the right message, delivered by the right KOL,
  in the right channel, for greater return on investment (ROI).
- The ElevatedRelevance® Decision Engine (Ele)
   Ele combines real-world data and proprietary algorithms driving campaign-specific, actionable, market and audience insights.
- Treatment Perspectives HCP Network
   Relevate Health's proprietary and HCP-recognized network
   providing unrivaled access to 1.4+MM prescribers and their
   2.3+MM associated treatment team members.

#### WHEN TO USE

 Brands seek access to engage hospital and outpatient HCPs with patient-relevant messaging during patient visit

# **REASONS TO BELIEVE**

- Business rules drive the right message to the right HCP at the right time in the EHR workflow
- Access to ~60% of the EHR-user HCP universe

# **METRICS AND PROOF POINTS**

- 20%-110% increase in eRx
- Guaranteed engagement based on business rules

# **HOW IS IT DELIVERED?**

Creative, text, and financial messages are delivered through the Treatment Perspectives EHR Network reaching 60%+ of HCPs.

#### **Non-Personal Drivers**

EHR text content

## **MESSAGE FORMATS**



NOVIATE™ (colorium) can be started at the full dose in patients with platelets ≥50 x 10<sup>9</sup>/L. Recommended daily dose is 400 mg (four 100-mg capsules) taken orally and given once daily. Learn more about dosing and dosing modifications in response to adverse events in the NOVIATE clinical and safety information.

Access full NOVIATE Prescribing Information.

© 2022 Impact Biomedicines, Inc. 01/22 2010-US-2200004

#### INDICATION

NOVIATE™ (colorium) is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or post-essential thrombocythemia) myelofibrosis (MF).

IMPORTANT SAFETY INFORMATION

# WHY PARTNER WITH US?

#### Proven, Measurable Result

Integrated real-time measurement and reporting framework using industry and proprietary benchmarks for campaign performance (ROI), reporting (aggregate and physician-Level data) and optimization

# Video and Event Production

Full video production capabilities, a proprietary broadcast/ webcast system, and a nationwide network of studios, event sites, technicians, and onsite meeting planners

#### Solution-Driven Portfolio

Innovative solutions that meet regulatory and compliance standards

Peer-to-peer	Non-Personal	Field Enablement
Treatment     Perspectives     National     Broadcast     PracticeShare     by Treatment     Perspectives     mChat	<ul> <li>Treatment Perspectives OnDemand</li> <li>Treatment Perspectives KAM</li> <li>Treatment Perspectives EHR</li> <li>Treatment Perspectives Interactive Quiz</li> <li>Treatment Perspectives Newsletter</li> </ul>	<ul><li>FieldShare</li><li>MyDoc</li><li>REPCast</li><li>KOLCast</li><li>Expert Exchange</li></ul>

### White Glove Customer Service

Single point of contact who understands the brand strategy and business

# Pharma-trained Delivery and Project Management Teams Multidisciplinary specialists to ensure that the program is Description of the program of the program

developed and delivered in alignment with brand strategy, on time, and on budget

Award Winning and Nationally Recognized Expertise
 Strategy, creative, analytics, user interface, user experience, development, SEO/SEM, and mobile to guide the success of the program

\*Data on file; Relevate Health 1st party Campaign data









3825 Edwards Road, 6th Floor | Cincinnati, OH 45209 connect@relevatehealth.com | 513.864.8900